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Background: Chromosomal instability is a hallmark of human cancer caused by errors in mitotic control and
chromosome segregation. STAG2 encodes a subunit of the cohesion complex that participates in mitotic chromatid
separation and was recently found to show low expression and inactivating mutations in Ewing’s sarcoma,
melanoma and glioblastoma.
In the childhood tumor neuroblastoma (NB) segmental chromosomal alterations are associated with poor prognosis
whereas tumors displaying whole chromosome gains and losses have a much better prognosis.
Method: As the genetic contribution to aneuploidy is unknown in NB, we investigated the presence of STAG2
mutations through sequence analysis of all 33 coding exons in 37 primary NB tumors.
Results and conclusion: As no STAG2 mutation was detected in this study, we conclude that inactivating
mutation of STAG2 is not likely causative to neuroblastoma aneuploidy.
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Chromosome instability leading to numerical and segmen-
tal alteration is a hallmark of human cancer genomes, con-
tributing to malignant transformation. Whereas segmental
rearrangements directly can promote cancer through
activating oncogenes and inactivating tumors suppressor
genes, aneuploidy could provide a tumor driving function
through dosage-dependent mechanisms [1]. Aneuploidy
is caused by inaccurate chromosome segregation, pos-
sibly due to genetic alteration of various participants of
the segregation or mitotic checkpoint machinery. Recently,
Solomon et al., showed the presence of inactivating muta-
tions in the STAG2 gene located at Xq25 in primary tu-
mors and cancer cell lines originating from glioblastoma,
melanoma and Ewing’s sarcoma. The STAG2 mutations
reported by Solomon et al., represented an array of differ-
ent alterations (missense-, nonsense-, splice site mutations
as well as intragenic deletions), mainly concentrated to* Correspondence: tommy.martinsson@gu.se
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reproduction in any medium, provided the orhotspot regions corresponding to exon 9, 11, 12 and 20
[2]. STAG2 encodes a subunit of the multimeric cohesion
complex required in regulating sister chromatid separation
during mitosis [3-5]. Inactivation of STAG2 in cell lines
with stable karyotype resulted in increased number of ab-
normal mitotic events (e.g. lagging chromosomes and ana-
phase bridges) ultimately leading to increased aneuploidy
rate while mutational correction of endogenous STAG2
mutations in aneuploid cell lines resulted in enhanced
chromosomal stability. Further, loss of STAG2 protein was
observed in several human cancer cell lines, primary
tumors and xenografts of different origin [2].
Neuroblastoma (NB), a childhood cancer of the post-
ganglionic nervous system show broad biological and clin-
ical heterogeneity, ranging from highly aggressive tumors
with fatal outcome to tumors with spontaneous regres-
sion. Advanced disease and poor prognosis in NB patients
is commonly associated with either MYCN amplification
or 11q-deletion, representing two separate NB subgroups
with different genomic profiles. WhereasMYCN amplified
tumors commonly have few segmental or numerical aber-
rations besides 17q-gain and 1p-deletions, 11q-deleted NB
generally contains many more segmental alterations. Ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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whole chromosome gains and/or losses) without other
segmental alterations instead have excellent outcome [6]
and the underlying mechanisms causing aneuploidy in NB
tumors are yet unknown.Table 1 Clinical and biological data of the tumors
Sample INSS INRG Gender 1p-del MNA 11q-del
3E2 4 M Ma neg neg pos
4E1 4 M F neg neg pos
5E1 2A L F neg neg neg
6E9 3 L Ma pos neg pos
8E4 1 L F neg neg neg
8E5 3 L F neg neg neg
11E1 4 M F neg neg pos
11E4 4 M F neg neg pos
11E8 1 L Ma neg neg neg
12E5 4S MS Ma neg neg neg
13E7 4S MS F neg neg neg
15E7 3 L Ma neg neg neg
16E1 1 L F neg neg neg
16E2 4S L Ma neg neg neg
17E5 4 M F neg neg neg
18E2 1 L F neg neg pos
18E5 1 L F neg neg neg
9R9 3 M F pos neg pos
10R6 2A L Ma neg neg neg
10R8 3 L F neg neg pos
13R1 3 L Ma pos pos neg
15R8 3 M Ma pos neg pos
23R4 2 L F neg neg neg
25R6 4 M Ma pos pos neg
25R7 1 L Ma pos neg neg
26R1 1 L Ma neg neg neg
27R1 2A L F neg neg neg
27R7 2 L Ma neg neg neg
28R8 4 M Ma neg neg pos
30R0 4 M F neg neg pos
34R5 3 L Ma neg neg neg
37R5 1 L Ma neg neg neg
44R5 1 L F neg neg neg
46R6 4 M Ma neg neg pos
47R4 4 M F neg neg pos
49R1 4 M Ma neg neg pos
52R2 1 L Ma neg neg neg
Abbreviations: INSS International Neuroblastoma Staging System [7], INRG Internatio
female, neg negative, pos positive, MNA NMYC-amplification, NED no evidence of di
by Carén et al [6].As the findings of Solomon et al [2] indicate that loss
of functional STAG2 protein could contribute to in-
creased chromosomal instability we wanted to investi-
gate the presence of inactivating mutations in STAG2 in
prognostically favorable NB with common aneuploidy17q-gain Genomic profile* 5-year OS Sanger NGS
pos 11q-del DOD +
pos 11q-del DOD +
neg Num only NED +
pos 11q-del DOD +
neg Num only NED +
neg Num only NED +
pos 11q-del NED +
pos 11q-del DOD +
neg Num only NED + +
neg Num only NED +
neg Num only NED +
neg Num only DSC +
neg Num only NED +
neg Num only NED +
neg Num only DOD +
pos 11q-del NED +
neg Num only NED +
pos 11q-del DOD +
neg Num only NED +
neg Num only DOD +
pos MNA DOD +
pos 11q-del NED +
neg Num only NED +
pos MNA DOD +
neg Other segm. NED +
neg Num only NED +
neg Num only NED +
neg Num only NED +
pos 11q-del DOD +
neg 11q-del NED +
neg Num only NED +
neg Num only NED +
neg Num only NED +
pos 11q-del NED +
pos 11q-del NED +
pos 11q-del NED +
pos 17q-gain NED +
nal Neuroblastoma Risk Group [8], M metastatic, L localized, Ma male, F
sease, DOD dead of disease, DSC dead of surgical complications. *As defined
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degree of segmental alteration.
Methods
Cell material
Genomic DNA of 37 primary NB tumors and cell lines
was extracted with DNeasy blood and tissue kit (Qiagen,
Hilden Germany) according to the manufacturer’s in-
structions. Mutation analysis through Sanger sequencing
of the 33 coding exons (3-35) of STAG2 was performed
on 18 favorable NB tumor samples (stage 1, 2 and 4S),
whereas additional 19 tumors of different risk groups
were subjects for whole exome sequencing whereof one
was also evaluated through Sanger sequencing (Table 1).
In addition, mutation analysis with Sanger sequencing
was performed on eleven NB cell lines (Table 2) SK-N-AS,
SK-N-BE(2), SK-N-F1, SH-SY-5Y, SK-N-SH, SK-N-DZ,
NB69, Kelly, IMR32, LS and NGP) for exons 3, 9, 11, 12,
20, 23 and 25. Informed consent was obtained from the
parents of the patients. Ethical permission was granted
by the ethics committee (Karolinska Institutet and
Karolinska University Hospital, registration number 03-736
and 09-1369).
High resolution SNP array analysis
Genomic profiling of the 37 primary NB tumors (Table 1,
Figure 1) were performed with Genechip Human Mapping
250K NspI (Affymetrix Inc., Santa Clara, CA) according to
the experimental procedure previously described [9].
Sanger sequencing
Sanger sequencing was performed as earlier described
[10] and primers were designed manually or with the
use of ExonPrimer (http://ihg.gsf.de/ihg/ExonPrimer.html),
primer sequences are available upon request. The se-
quence data were analyzed using Seqscape v2.5 (Applied
Biosystems).Table 2 Characteristics of the cell lines
Cell line Gender 1p-del MNA 11q-del 17q-gain ChrX
NGP Ma neg pos pos pos one
Kelly F neg pos pos pos one
LS F neg pos neg pos two
SH-SY-5Y F neg neg neg pos two
NB69 Ma pos neg neg pos one
SK-N-FI Ma neg neg neg pos one
SK-N-AS F pos neg pos pos one
IMR32 Ma pos pos neg pos one
SK-N-BE Ma neg pos neg pos one
SK-N-DZ F neg pos pos neg two
SK-N-SH F neg neg neg pos two
Abbreviations: Ma male, F female, neg negative, pos positive.Exome sequencing
Whole exome capturing was made with 5 μg gDNA
using SureSelect Human All Exon Target Enrichment
System 3.0 (Agilent Technologies, Santa Clara, CA) or
TrueSelect exome enrichment kit (Illumina, San Diego,
CA) before pair-end sequencing on Illumina HiScanSQ
or HighSeq2000. Alignment to the hg19 reference
genome (http://genome.ucsc.edu/) was performed using
BWA [11], indel realignment with GATK [12] while
functional variant annotation was made through
ANNOVAR [13]. Visualisation for manual reviewing of
alignments was performed using the DNAnexus software
(DNAnexus Inc. Mountain View, CA) or the Integrative
Genomic Viewer [14].Results
The coding sequence of the STAG2 gene was screened
with Sanger sequencing and targeted re-sequencing in a
panel of 37 NB tumors and eleven NB cell lines (Tables 1
and 2). High-quality sequence of the STAG2 gene was
obtained for all 33 coding exons both from Sanger- and
exome sequencing. Sequences with an average coverage
of 51x (range 13-117x) were acquired from all coding
exons in tumors analyzed by exome sequencing.
One of 37 primary tumors (11E8) and one of eleven
NB cell lines (SK-N-DZ) showed a hemizygous and het-
erozygous base substitution respectively corresponding
to C>T at mRNA position 1298-9 in intron 10 (Figure 2),
similar to a finding earlier reported in a glioblastoma
primary xenograft [2]. However, this variant correspond-
ing to SNP rs7063522, was also present in normal DNA
from patient’s blood (Figure 2). No exonic variants were
detected in our set of 37 NB tumors and 11 NB cell lines,
neither in the hot spot positions reported by Solomon et al.,
nor in any other coding region of the STAG2 gene [2].Discussion
Aneuploidy results from missegregation of sister chro-
matids during mitotic cell division. In NB segmental
chromosomal alterations are common in aggressive tu-
mors whereas tumors with only whole chromosome
gains and losses are prognostically more favorable [6].
However, the cause of the high aneuploidy rate in this
favorable group of NB tumors is currently unknown.
Aneuploidy is also frequently observed in other malig-
nancies and recently STAG2 was recognized as a tumor
suppressor gene causing malfunctioning mitotic sister
chromatid separation when inactivated. Inactivating muta-
tions of STAG2 have been found in glioblastoma, Ewing’s
sarcoma and melanoma, possibly contributing to chromo-
some instability in these tumors [2] and this led us to
investigate whether they might also be responsible for the
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Figure 1 SNP array genomic profiles of four representative Neuroblastoma tumors with numerical aberrations. The total copy numbers
of each chromosome are shown by the upper multicolored line and the red and green lower lines represent the strongest (red) and weakest
(green) allele specific intensity.
Djos et al. BMC Medical Genetics 2013, 14:102 Page 4 of 6
http://www.biomedcentral.com/1471-2350/14/102In the present study, we sequenced all 33 coding exons
of the STAG2 gene in 11 NB cell lines and 37 primary
NB tumors and no deviation from the human reference
sequence could be detected. This is similar to other re-
cent studies of the STAG2 mutational hot spot region(corresponding to exon 9, 11, 12 and 20) in 90 acute
leukemia samples [15] and 225 adult carcinomas of vari-
ous origin (colorectal-, gastric-, breast-, prostate carcin-
oma and non-small lung cell cancer) [16]. Alteration of
STAG2 was not detected in either study, suggesting that
Figure 2 A hemizygous/homozygous base substitution corresponding to SNP rs7063522 detected in intron 10. A) Upper and lower
panel show results from exon sequencing of tumor and blood DNA respectively from NB patient 11E8. B) Upper and middle panel show results
from Sanger sequencing of the same NB patient’s tumor and blood DNA respectively, lower panel show result from Sanger sequencing of the NB
cell line SK-N-DZ. Bars under the electropherograms show the position of the base substitution.
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http://www.biomedcentral.com/1471-2350/14/102STAG2 inactivation is not due to inactivating gene
mutations in these malignancies. Other gene silencing
mechanisms might contribute as STAG2 protein was lost
in 23-30% of studied carcinomas [16].
According to the publicly accessible R2-microarray
analysis and visualization platform (http://r2.amc.nl),
STAG2 expression in NB can be correlated with out-
come in that lower STAG2 expression is correlated to
lower overall survival and relapse free survival. Other
causes than STAG2 mutations are likely to be involved
in this, e.g. epigenetic events.
Furthermore, previous and subsequent analyzes of
copy number variations performed by us in totally 360
primary NB tumors show that segmental deletions of
the chromosomal region Xq25 harboring STAG2 are not
seen ([6] and unpublished data).
Taken together these data suggest that STAG2 muta-
tions are not likely responsible for the high aneuploidy
rate in NB tumors with numerical aberrations. However,
other genes participating in the mitotic checkpoint
control may be responsible for the chromosomal
missegregation in NB tumors with many numerical
aberrations.
Three major next generation sequencing studies have
together analyzed a large serie of NB tumors [17-19]. No
STAG2 mutations are reported and overall very few
recurrent amino-acid changing mutations were found.
Molenaar et al. [17], found few recurrent mutationsexcept for the genes ALK and TIAM1 and mutations
in genes regulating neuritogenes. Cheung et al. [18],
reported the finding of deletions and loss-of-function
mutations in the ATRX gene and the association with
advanced age at NB diagnosis. Furthermore, Sausen
et al. [19], found mutations and deletions in the genes
ARID1A and ARID1B which were associated with treat-
ment failure and poor prognosis. Collectively more
recurrent somatic mutation have been found in high risk
NB patients compared to patients with stage 1, 2 and 4S
tumors and in the published NGS data we cannot iden-
tify clear candidate genes that could be responsible for
the high aneuploidy rate seen in favorable NB.Conclusion
Here we show that inactivating point mutations in the
STAG2 gene are not common in NB tumors and that
aneuploidy seen in NB tumors is likely due to other par-
ticipants of the mitotic checkpoint and chromosome
segregation machinery.
Competing interests
The authors declare they have no conflict of interests.
Authors’ contributions
AD and SF performed experiments, analysis and wrote the paper. TM
coordinated the project, critically reviewed the manuscript and provided
biological and clinical information together with PK. All authors read and
approved the final manuscript.
Djos et al. BMC Medical Genetics 2013, 14:102 Page 6 of 6
http://www.biomedcentral.com/1471-2350/14/102Acknowledgements
We would like to thank the Genomics and Bioinformatics core facilities at
University of Gothenburg and the SciLifeLab, Stockholm for access to
instruments. We also thank Rose-Marie Sjöberg for excellent technical
assistance. This work was supported by grants from the Swedish Cancer
Society, the Swedish Children’s Cancer Foundation, the Sahlgrenska
University Hospital Foundation, the Swedish state through the LUA/ALF
agreement, and the Assar Gabrielsson Foundation.
Author details
1Department of Clinical Genetics, Institute of Biomedicine, University of
Gothenburg, Sahlgrenska University Hospital, SE-413 45 Gothenburg,
Sweden. 2Childhood Cancer Research Unit, Department of Woman and Child
Health, Karolinska Institute, Karolinska University Hospital, SE-17176
Stockholm, Sweden.
Received: 4 March 2013 Accepted: 23 September 2013
Published: 2 October 2013
References
1. Gordon DJ, Resio B, Pellman D: Causes and consequences of aneuploidy
in cancer. Nat Rev Genet 2012, 13(3):189–203.
2. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT,
Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, et al: Mutational
inactivation of STAG2 causes aneuploidy in human cancer. Science 2011,
333(6045):1039–1043.
3. Carramolino L, Lee BC, Zaballos A, Peled A, Barthelemy I, Shav-Tal Y, Prieto I,
Carmi P, Gothelf Y, Gonzalez De Buitrago G, et al: SA-1, a nuclear protein
encoded by one member of a novel gene family: molecular cloning and
detection in hemopoietic organs. Gene 1997, 195(2):151–159.
4. Sumara I, Vorlaufer E, Gieffers C, Peters BH, Peters JM: Characterization of
vertebrate cohesin complexes and their regulation in prophase.
J Cell Biol 2000, 151(4):749–762.
5. Haering CH, Farcas AM, Arumugam P, Metson J, Nasmyth K: The cohesin
ring concatenates sister DNA molecules. Nature 2008, 454(7202):297–301.
6. Caren H, Kryh H, Nethander M, Sjoberg RM, Trager C, Nilsson S,
Abrahamsson J, Kogner P, Martinsson T: High-risk neuroblastoma tumors
with 11q-deletion display a poor prognostic, chromosome instability
phenotype with later onset. Proc Natl Acad Sci USA 2010,
107(9):4323–4328.
7. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De
Bernardi B, Evans AE, Favrot M, Hedborg F, et al: Revisions of the
international criteria for neuroblastoma diagnosis, staging, and response
to treatment. J Clin Oncol 1993, 11(8):1466–77.
8. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K,
Kaneko M, London WB, Matthay KK, Nuchtern JG, et al: The International
Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force
report. J Clin Oncol 2009, 27:298–303.
9. Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg RM, Abrahamsson J,
Kogner P, Martinsson T: High-resolution array copy number analyses for
detection of deletion, gain, amplification and copy-neutral LOH in
primary neuroblastoma tumors: four cases of homozygous deletions of
the CDKN2A gene. BMC Genomics 2008, 9:353.
10. Caren H, Abel F, Kogner P, Martinsson T: High incidence of DNA mutations
and gene amplifications of the ALK gene in advanced sporadic
neuroblastoma tumours. Biochem J 2008, 416(2):153–159.
11. Li H, Durbin R: Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 2009, 25(14):1754–1760.
12. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A,
Garimella K, Altshuler D, Gabriel S, Daly M, et al: The Genome Analysis
Toolkit: a MapReduce framework for analyzing next-generation DNA
sequencing data. Genome Res 2010, 20(9):1297–1303.
13. Wang K, Li M, Hakonarson H: ANNOVAR: functional annotation of genetic
variants from high-throughput sequencing data. Nucleic Acids Res 2010,
38(16):e164.
14. Thorvaldsdottir H, Robinson JT, Mesirov JP: Integrative Genomics Viewer
(IGV): high-performance genomics data visualization and exploration.
Brief Bioinform 2013, 4(2):178–92.
15. Chung NG, Kim MS, Yoo NJ, Lee SH: Somatic mutation of STAG2, an
aneuploidy-related gene, is rare in acute leukemias. Leuk Lymphoma
2012, 53(6):1234–1235.16. Kim MS, Kim SS, Je EM, Yoo NJ, Lee SH: Mutational and expressional
analyses of STAG2 gene in solid cancers. Neoplasma 2012, 59(5):524–529.
17. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der
Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, et al: Sequencing
of neuroblastoma identifies chromothripsis and defects in
neuritogenesis genes. Nature 2012, 483(7391):589–93.
18. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo
AS, Federico S, Dalton J, et al: Association of age at diagnosis and genetic
mutations in patients with neuroblastoma. JAMA 2012, 307(10):1062–71.
doi:10.1001/jama.2012.228.
19. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, Blackford A,
Parmigiani G, Diaz LA Jr, Papadopoulos N, et al: Integrated genomic
analyses identify ARID1A and ARID1B alterations in the childhood cancer
neuroblastoma. Nat Genet 2013, 45(1):12–7.
doi:10.1186/1471-2350-14-102
Cite this article as: Djos et al.: Aneuploidy in neuroblastoma tumors is
not associated with inactivating point mutations in the STAG2 gene.
BMC Medical Genetics 2013 14:102.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
